187 related articles for article (PubMed ID: 29862486)
1. Determinants of the beneficial effect of mineralocorticoid receptor antagonism on exercise capacity in heart failure with reduced ejection fraction.
Dankowski R; Kotwica T; Szyszka A; Przewłocka-Kosmala M; Sacharczuk W; Karolko B; Kobusiak-Prokopowicz M; Mysiak A; Kosmala W
Kardiol Pol; 2018; 76(9):1327-1335. PubMed ID: 29862486
[TBL] [Abstract][Full Text] [Related]
2. Association of Active and Passive Components of LV Diastolic Filling With Exercise Intolerance in Heart Failure With Preserved Ejection Fraction: Mechanistic Insights From Spironolactone Response.
Kosmala W; Przewlocka-Kosmala M; Marwick TH
JACC Cardiovasc Imaging; 2019 May; 12(5):784-794. PubMed ID: 29248640
[TBL] [Abstract][Full Text] [Related]
3. Effect of Aldosterone Antagonism on Exercise Tolerance in Heart Failure With Preserved Ejection Fraction.
Kosmala W; Rojek A; Przewlocka-Kosmala M; Wright L; Mysiak A; Marwick TH
J Am Coll Cardiol; 2016 Oct; 68(17):1823-1834. PubMed ID: 27765184
[TBL] [Abstract][Full Text] [Related]
4. The Effectiveness of Eplerenone vs Spironolactone on Left Ventricular Systolic Function, Hospitalization and Cardiovascular Death in Patients With Chronic Heart Failure-HFrEF.
Naser N; Durak-Nalbantic A; Sabanovic-Bajramovic N; Karic A
Med Arch; 2023 Apr; 77(2):105-111. PubMed ID: 37260796
[TBL] [Abstract][Full Text] [Related]
5. Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure.
Mottram PM; Haluska B; Leano R; Cowley D; Stowasser M; Marwick TH
Circulation; 2004 Aug; 110(5):558-65. PubMed ID: 15277317
[TBL] [Abstract][Full Text] [Related]
6. Differential interaction of clinical characteristics with key functional parameters in heart failure with preserved ejection fraction--results of the Aldo-DHF trial.
Edelmann F; Gelbrich G; Duvinage A; Stahrenberg R; Behrens A; Prettin C; Kraigher-Krainer E; Schmidt AG; Düngen HD; Kamke W; Tschöpe C; Herrmann-Lingen C; Halle M; Hasenfuss G; Wachter R; Pieske B
Int J Cardiol; 2013 Nov; 169(6):408-17. PubMed ID: 24182675
[TBL] [Abstract][Full Text] [Related]
7. Usefulness of myocardial work measurement in the assessment of left ventricular systolic reserve response to spironolactone in heart failure with preserved ejection fraction.
Przewlocka-Kosmala M; Marwick TH; Mysiak A; Kosowski W; Kosmala W
Eur Heart J Cardiovasc Imaging; 2019 Oct; 20(10):1138-1146. PubMed ID: 31502637
[TBL] [Abstract][Full Text] [Related]
8. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial.
Edelmann F; Wachter R; Schmidt AG; Kraigher-Krainer E; Colantonio C; Kamke W; Duvinage A; Stahrenberg R; Durstewitz K; Löffler M; Düngen HD; Tschöpe C; Herrmann-Lingen C; Halle M; Hasenfuss G; Gelbrich G; Pieske B;
JAMA; 2013 Feb; 309(8):781-91. PubMed ID: 23443441
[TBL] [Abstract][Full Text] [Related]
9. Randomized, double-blind, multicenter, placebo-controlled study evaluating the effect of aldosterone antagonism with eplerenone on ventricular remodeling in patients with mild-to-moderate heart failure and left ventricular systolic dysfunction.
Udelson JE; Feldman AM; Greenberg B; Pitt B; Mukherjee R; Solomon HA; Konstam MA
Circ Heart Fail; 2010 May; 3(3):347-53. PubMed ID: 20299607
[TBL] [Abstract][Full Text] [Related]
10. Effect of mineralocorticoid receptor antagonists on cardiac function in patients with heart failure and preserved ejection fraction: a systematic review and meta-analysis of randomized controlled trials.
Kapelios CJ; Murrow JR; Nührenberg TG; Montoro Lopez MN
Heart Fail Rev; 2019 May; 24(3):367-377. PubMed ID: 30618017
[TBL] [Abstract][Full Text] [Related]
11. Long-term, dose-dependent effects of spironolactone on left ventricular function and exercise tolerance in patients with chronic heart failure.
Cicoira M; Zanolla L; Rossi A; Golia G; Franceschini L; Brighetti G; Marino P; Zardini P
J Am Coll Cardiol; 2002 Jul; 40(2):304-10. PubMed ID: 12106936
[TBL] [Abstract][Full Text] [Related]
12. Mechanistic Effects of Spironolactone on Cardiovascular and Renal Biomarkers in Heart Failure With Preserved Ejection Fraction: A TOPCAT Biorepository Study.
Myhre PL; Vaduganathan M; O'Meara E; Claggett BL; de Denus S; Jarolim P; Anand IS; Pitt B; Rouleau JL; Solomon SD; Pfeffer MA; Desai AS
Circ Heart Fail; 2020 Jan; 13(1):e006638. PubMed ID: 31957468
[TBL] [Abstract][Full Text] [Related]
13. Beneficial neurohormonal profile of spironolactone in severe congestive heart failure: results from the RALES neurohormonal substudy.
Rousseau MF; Gurné O; Duprez D; Van Mieghem W; Robert A; Ahn S; Galanti L; Ketelslegers JM;
J Am Coll Cardiol; 2002 Nov; 40(9):1596-601. PubMed ID: 12427411
[TBL] [Abstract][Full Text] [Related]
14. IMproved exercise tolerance in patients with PReserved Ejection fraction by Spironolactone on myocardial fibrosiS in Atrial Fibrillation rationale and design of the IMPRESS-AF randomised controlled trial.
Shantsila E; Haynes R; Calvert M; Fisher J; Kirchhof P; Gill PS; Lip GY
BMJ Open; 2016 Oct; 6(10):e012241. PubMed ID: 27707827
[TBL] [Abstract][Full Text] [Related]
15. Effect of If-channel inhibition on hemodynamic status and exercise tolerance in heart failure with preserved ejection fraction: a randomized trial.
Kosmala W; Holland DJ; Rojek A; Wright L; Przewlocka-Kosmala M; Marwick TH
J Am Coll Cardiol; 2013 Oct; 62(15):1330-8. PubMed ID: 23916925
[TBL] [Abstract][Full Text] [Related]
16. Results of the Randomized Aldosterone Antagonism in Heart Failure with Preserved Ejection Fraction trial (RAAM-PEF).
Deswal A; Richardson P; Bozkurt B; Mann DL
J Card Fail; 2011 Aug; 17(8):634-42. PubMed ID: 21807324
[TBL] [Abstract][Full Text] [Related]
17. PDE 5 inhibition with udenafil improves left ventricular systolic/diastolic functions and exercise capacity in patients with chronic heart failure with reduced ejection fraction; A 12-week, randomized, double-blind, placebo-controlled trial.
Kim KH; Kim HK; Hwang IC; Cho HJ; Je N; Kwon OM; Choi SJ; Lee SP; Kim YJ; Sohn DW
Am Heart J; 2015 Jun; 169(6):813-822.e3. PubMed ID: 26027619
[TBL] [Abstract][Full Text] [Related]
18. Biomarker-based phenotyping of myocardial fibrosis identifies patients with heart failure with preserved ejection fraction resistant to the beneficial effects of spironolactone: results from the Aldo-DHF trial.
Ravassa S; Trippel T; Bach D; Bachran D; González A; López B; Wachter R; Hasenfuss G; Delles C; Dominiczak AF; Pieske B; Díez J; Edelmann F
Eur J Heart Fail; 2018 Sep; 20(9):1290-1299. PubMed ID: 29709099
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Importance of Changes in Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone.
Shah AM; Claggett B; Sweitzer NK; Shah SJ; Deswal A; Anand IS; Fleg JL; Pitt B; Pfeffer MA; Solomon SD
Circ Heart Fail; 2015 Nov; 8(6):1052-8. PubMed ID: 26475142
[TBL] [Abstract][Full Text] [Related]
20. Different determinants of exercise capacity in HFpEF compared to HFrEF.
Batalli A; Ibrahimi P; Bytyçi I; Ahmeti A; Haliti E; Elezi S; Henein MY; Bajraktari G
Cardiovasc Ultrasound; 2017 Apr; 15(1):12. PubMed ID: 28446199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
